GSK PLC Sponsored ADR (NYSE:GSK – Get Free Report) has been assigned a consensus recommendation of “Hold” from the ten ratings firms that are currently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, six have issued a hold recommendation, one has assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $53.00.
GSK has been the subject of a number of recent research reports. Jefferies Financial Group raised GSK to a “strong-buy” rating in a report on Friday, July 17th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of GSK in a report on Thursday, July 30th. Weiss Ratings downgraded GSK from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday, July 29th. HSBC upgraded GSK from a “reduce” rating to a “hold” rating in a report on Monday, July 6th. Finally, Royal Bank Of Canada restated an “outperform” rating on shares of GSK in a research note on Tuesday, June 9th.
Check Out Our Latest Stock Analysis on GSK
GSK Stock Performance
GSK (NYSE:GSK – Get Free Report) last issued its quarterly earnings data on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.27 by $0.09. GSK had a net margin of 14.56% and a return on equity of 43.23%. The firm had revenue of $11.14 billion during the quarter, compared to analysts’ expectations of $11.02 billion. During the same period last year, the company earned $0.47 earnings per share. The business’s revenue was up 5.3% on a year-over-year basis. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. On average, analysts expect that GSK will post 4.83 EPS for the current fiscal year.
GSK Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Thursday, October 8th. Stockholders of record on Friday, August 14th will be issued a $0.4515 dividend. This is an increase from GSK’s previous quarterly dividend of $0.44. This represents a $1.81 annualized dividend and a dividend yield of 3.6%. The ex-dividend date is Friday, August 14th. GSK’s dividend payout ratio is currently 55.63%.
GSK News Summary
Here are the key news stories impacting GSK this week:
- Positive Sentiment: GSK agreed to license exclusive rights outside Mainland China, Hong Kong, Macau and Taiwan to Hutchmed’s experimental KRAS-EGFR antibody-drug conjugate, HMPL-A830. The deal includes a reported $110 million upfront payment and could be worth up to $1.295 billion in total milestone payments, giving GSK access to a potentially differentiated solid-tumor treatment. HUTCHMED signs licensing deal with GSK for experimental solid tumour drug
- Positive Sentiment: Deutsche Bank said GSK’s Phase II mRNA flu vaccine results closely track data from Moderna’s comparable candidate. The read-through supports the credibility of GSK’s vaccine platform and could strengthen expectations for a future product in the seasonal influenza market. GSK’s mRNA flu vaccine data closely tracks Moderna’s
- Neutral Sentiment: Coverage also points to solid first-half growth and continued support from the licensing transaction. However, HMPL-A830 is an experimental, early-stage asset, so GSK must fund further development and still faces clinical, regulatory and commercial execution risks before the program can generate revenue. GSK stock gains support from licensing deal and solid first-half growth
Institutional Investors Weigh In On GSK
A number of institutional investors have recently added to or reduced their stakes in GSK. IHT Wealth Management LLC increased its holdings in GSK by 1.3% in the 4th quarter. IHT Wealth Management LLC now owns 15,010 shares of the pharmaceutical company’s stock worth $736,000 after buying an additional 188 shares during the period. Bogart Wealth LLC boosted its holdings in shares of GSK by 15.3% in the 1st quarter. Bogart Wealth LLC now owns 1,508 shares of the pharmaceutical company’s stock valued at $83,000 after acquiring an additional 200 shares during the last quarter. Coston McIsaac & Partners increased its stake in shares of GSK by 17.3% in the fourth quarter. Coston McIsaac & Partners now owns 1,395 shares of the pharmaceutical company’s stock worth $68,000 after acquiring an additional 206 shares during the period. Natural Investments LLC raised its holdings in shares of GSK by 2.8% during the second quarter. Natural Investments LLC now owns 7,726 shares of the pharmaceutical company’s stock worth $405,000 after purchasing an additional 211 shares during the last quarter. Finally, HF Advisory Group LLC lifted its position in GSK by 3.5% during the second quarter. HF Advisory Group LLC now owns 7,578 shares of the pharmaceutical company’s stock valued at $397,000 after purchasing an additional 259 shares during the period. 15.74% of the stock is owned by institutional investors.
About GSK
GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.
GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.
Featured Articles
- Five stocks we like better than GSK
- AI Token Costs Are Changing the Hardware vs. Software Debate
- 3 ETFs That Could Move as Rate Expectations Shift
- 3 Stocks With September Catalysts Investors Shouldn’t Ignore
- Ollie’s Bargain Outlet Stock Falls on Weak Comps Despite Margin Gains
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
